A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Lumos Pharma
iOnctura
Artios Pharma Ltd
Engeneic Pty Limited
Verastem, Inc.
Esperas Pharma Inc.
Phanes Therapeutics
Immodulon Therapeutics Ltd
BioNTech SE
Altor BioScience
Aravive, Inc.
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
Chinese PLA General Hospital
Incyte Corporation
University of Maryland, Baltimore
Chinese PLA General Hospital
Eli Lilly and Company
Eli Lilly and Company
EMD Serono
Dana-Farber Cancer Institute
Threshold Pharmaceuticals